Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.59 |
| ▸ | BRD4 | O60885 | 7/20 | 0.59 |
| ▸ | JAK1 | P23458 | 1/20 | 0.58 |
| ▸ | BRD2 | P25440 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.53 |
| ▸ | CDK4 | P11802 | 7/20 | 0.52 |
| ▸ | CCND1 | P24385 | 6/20 | 0.52 |
| ▸ | CCND2 | P30279 | 6/20 | 0.52 |
| ▸ | CCND3 | P30281 | 6/20 | 0.52 |
| ▸ | WEE1 | P30291 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976815 | 0.87 | MAPK8 (0.61) | JAK2JAK3FGFR4CDK4CCND1 | |
| SCHEMBL3967843 | 0.87 | CDK4 (0.58) | JAK2BRD4JAK1BRD2JAK3 | |
| SCHEMBL3972215 | 0.85 | CDK4 (0.65) | JAK2BRD4FGFR4CDK4CCND1 | |
| SCHEMBL3972941 | 0.82 | CDK4 (0.66) | JAK2BRD4JAK1BRD2JAK3 | |
| SCHEMBL7856978 | 0.80 | WEE1 (0.54) | JAK2BRD4JAK1BRD2JAK3 | |
| SCHEMBL3970416 | 0.78 | CDK4 (0.55) | JAK2BRD4JAK3FGFR4CDK4 | |
| SCHEMBL3967315 | 0.76 | DCLK1 (0.49) | JAK2BRD4JAK1BRD2JAK3 | |
| SCHEMBL16570603 | 0.76 | JAK2 (0.66) | JAK2BRD4JAK1BRD2JAK3 | |
| SCHEMBL16570330 | 0.75 | JAK2 (0.68) | JAK2BRD4JAK1BRD2JAK3 | |
| SCHEMBL3970463 | 0.75 | CDK4 (0.81) | JAK2JAK1JAK3FGFR4CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | JAK2 469/4885BRD4 341/4885JAK1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.